Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5701571 | Journal of Thoracic Oncology | 2017 | 14 Pages |
Abstract
PD-L1 IHC can be performed on routine clinical lung cancer specimens. A TPS of at least 50% seldom overlaps with presence of driver oncogenes with approved targeted therapies. Three biomarker-specified groups of advanced lung adenocarcinomas can now be defined, each paired with a specific palliative first-line systemic therapy of proven clinical benefit: (1) EGFR/ALK/ROS1-affected adenocarcinoma paired with a matched tyrosine kinase inhibitor (â¼20% of cases), (2) PD-L1-enriched adenocarcinoma (TPS â¥50%) paired with anti-PD-1 pembrolizumab (â¼30% of cases), and (3) biomarker-negative (i.e., EGFR/ALK/ROS1/PD-L1-negative) adenocarcinoma paired with platinum doublet chemotherapy with or without bevacizumab (â¼50% of cases).
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Deepa MD, Paul A. MD, PhD, Meghan MD, Xiuning MD, PhD, Mark S. MD, Susumu S. MD, PhD, Daniel B. MD, PhD,